Article Versions Notes

De Oliveira DMP, Keller B, Hayes AJ, Ong C-LY, Harbison-Price N, El-Deeb IM, Li G, Keller N, Bohlmann L, Brouwer S, et al. Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria. Antibiotics. 2022; 11(4):449. https://doi.org/10.3390/antibiotics11040449

De Oliveira, David M. P., Bernhard Keller, Andrew J. Hayes, Cheryl-Lynn Y. Ong, Nichaela Harbison-Price, Ibrahim M. El-Deeb, Gen Li, Nadia Keller, Lisa Bohlmann, Stephan Brouwer, and et al. 2022. "Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria" Antibiotics 11, no. 4: 449. https://doi.org/10.3390/antibiotics11040449

De Oliveira, D. M. P., Keller, B., Hayes, A. J., Ong, C.-L. Y., Harbison-Price, N., El-Deeb, I. M., Li, G., Keller, N., Bohlmann, L., Brouwer, S., Turner, A. G., Cork, A. J., Jones, T. R., Paterson, D. L., McEwan, A. G., Davies, M. R., McDevitt, C. A., Itzstein, M. v., & Walker, M. J. (2022). Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria. Antibiotics, 11(4), 449. https://doi.org/10.3390/antibiotics11040449